Telix Pharmaceuticals (ASX:TLX) received marketing authorization in France for Illuccix, its prostate cancer positron emission tomography (PET) imaging agent, the company said in a statement Monday.
Illucix is indicated in France for the detection and localization of prostate-specific membrane antigen-positive lesions in adults with prostate cancer, the statement said.
The company is partnering with IRE Group subsidiary IRE ELiT to market and promote Illuccix in France, according to the statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.